7 results about "Gastrointestinal system" patented technology

The present invention provides an injectable depot composition comprising linagliptin and low-dose liraglutide. The combination therapy of linagliptin and low-dose liraglutide provides a synergistic effect in the treatment of obesity compared to the administration of each drug alone. In addition, the administration dose of liraglutide can be reduced compared to the administration of liraglutide alone, and thus the direct cause of side effects related to the gastrointestinal system and the cardiovascular system of liraglutide can be reduced. Furthermore, by the combination of linagliptin, it has the advantage of additionally providing an improvement effect on metabolic diseases and cardiovascular diseases related to blood sugar, blood lipids, blood pressure, fatty liver, etc. In addition, compared to the conventional liraglutide dosage form of once-daily subcutaneous injection, the depot composition of linagliptin and liraglutide of the present invention can significantly improve patient convenience and patient compliance by unifying the administration route and improving the administration cycle.

There is an innovative cockroach killer consisting of two active chemical substances (one in salt form composed of sodium ions and bicarbonate ions, and the other in powdered sugar form). Their chemical formulas are NaHCO3 ( fig.2) and C12H22O11 ( fig.1), respectively and are available in powder form or in specific plastic trapping containers. The product in question is placed in indoor and outdoor areas. The sweet taste of the first chemical substance C12H22O11 attracts the cockroach to taste it; taking a small dose, the above substance passes through the salivary glands and liquefies; after liquefaction, the second chemical substance NaHCO3 starts to act and expand internally in the cockroach's gastrointestinal system, causing swelling and immediate extermination of said insect.

The application belongs to the technical field of food manufacturing, and specifically discloses a preparation method of fermented flower and fruit juice drink, which uses solid-liquid secondary fermentation as a technical means, and performs solid fermentation on dehydrated, kneaded and sterilized fresh flowers by connecting the fermentation bacteria, grinds the flower petals after fermentation, and obtains the leaching liquor through water extraction, mixes the leaching liquor with fruit juice, and then performs liquid fermentation, and obtains the fermented flower and fruit juice through sterilization, compounding, homogenization and clarification. The application uses different types of probiotics in combination with the preparation method of solid-liquid fermentation, effectively improves the free radical removal rate, total phenol content and polyphenol bioavailability in the flower and fruit juice, and thus improves the antioxidant activity and nutritional value of the flower and fruit juice; meanwhile, a large amount of flavor substances and nutritional substances are produced in the fermentation process, and the substances interact with each other to produce rich metabolic products, and the nutritional quality and flavor diversity of the flower and fruit juice are improved; the secondary fermentation also brings a large amount of active probiotics, and has the effects of helping digestion and adjusting the gastrointestinal system.

The present invention provides an obesity treatment regimen for reducing side effects by low-dose combination administration of linagliptin and liraglutide. The combination therapy of linagliptin and low-dose liraglutide provides a synergistic effect in obesity treatment compared to administration of each drug alone. Furthermore, the administration dose of liraglutide can be reduced compared to administration of liraglutide alone, and thus the direct cause of side effects related to the gastrointestinal system and the cardiovascular system of liraglutide can be reduced. Furthermore, by the combination of linagliptin, it has the advantage of additionally providing an improvement effect on metabolic diseases and cardiovascular diseases related to blood sugar, blood lipids, blood pressure, fatty liver, etc.

Methods of treating cancer of the digestive system, preferably of the gastrointestinal system, in a patient using an anti-GUCY2CxCD3 antibody are disclosed.

A method for treating the gastrointestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

The invention relates to a preoperative simulation and evaluation method for gastrointestinal system reconstruction, which comprises the following steps of: acquiring multi-source preoperative clinical data, identifying stress and strain response trajectories formed in a lesion process of gastrointestinal tissues, and calibrating a structural response lag region in the gastrointestinal tissues so as to determine an adjustable tissue boundary range; synthesizing tissue deformation adaptability, anatomical continuity and adjacent organ space constraint conditions, and screening a plurality of anatomical pathways as reconstruction candidate paths; evaluating the stress concentration trend of the anastomotic stoma and the peripheral area in the postoperative stage based on the candidate paths in combination with the operation parameters of a traction angle, suture displacement and tension transfer generated in the operation, identifying the area with potential structural fatigue or deformation accumulation risk, and establishing strain adaptability indexes corresponding to the paths; by analyzing the pressure distribution pattern and the peristalsis direction of the gastrointestinal system of a patient, a pressure migration intersection point caused by structural adjustment is identified, and in combination with a path change trend, a potential fluid backflow, pressure accumulation or negative pressure interference risk area existing after anastomosis is judged.